`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ARGENTUM PHARMACEUTICALS LLC,
`
`Petitioner,
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.,
`Patent Owner.
`
`Case No. IPR2016—00204
`
`Patent No. RE 38,551
`
`PATENT OWNER’S EXHIBIT LIST
`
`
`
`IPR2016—00204
`
`029819.0100-US03
`
`LIST OF EXHIBITS
`
`Exhibit
`
`Description
`
`2001
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`i2011
`
`2012
`
`L
`
`Richard H. Mattson, Efficacy and Adverse Effects ofEstablished and
`New Antiepileptic Drugs, 36 (Suppl. 2) Epilepsia S13-S26 (1995).
`
`Richard H. Mattson, Drug Treatment of Uncontrolled Seizures, in
`Surgical Treatment of Epilepsy 29-35 (William H. Theodore ed.,
`1992).
`
`FDA Approved Labeling Text dated August 27, 2012 for
`FELBATOL® (felbamate) , available at
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/0201893
`027lbl.pdf (last visited Feb. 2, 2016).
`
`Judith D. Conley & Harold Kohn, Functionalized DL—Amino Acid
`Derivatives. PotentNew Agents for the Treatment ofEpilepsy, 30 J.
`
`(Med. Chem. 567~574 (1987).
`
`U.S. Provisional Patent Application No. 60/013,522.
`
`l
`
`Bialer et al., Progress report on new antiepileptic drugs: a summary
`of the Sixth Eilat Conference (EILAT VI), 51 Epilepsy Res. 31-71
`(2002).
`
`Jerry March, Advanced Organic Chemistry 94-96 (4th ed. 1992).
`
`Decision Denying Institution of Inter Partes Review, IPR2014—
`01126, Paper 22.
`
`Curriculum Vitae of Dr. Farrokh Mistree, September 2014.
`
`Marcy Barge & W.T. Ingram, Inverse Limits on [0,1] Using Logistic
`Bonding Maps, 72 Topology and its Applications 159-72 (1996).
`
`Jack McBryde Jr., Inverse Limits on Arcs Using Certain Logistic
`
`Maps as Bonding Maps, Master’s Thesis, University of Houston,
`(1987).
`
`Trial Testimony of Dr. Clayton Heathcock, UCB, Inc., et al., v.
`Accord Healtheare, Ine., et. al., No. 13-1206-LPS (D. Del., Nov. 9,
`2015).
`
`
`
`IPR2016—00204
`
`I
`
`Exhibit
`_____.._.._______l____.___
`
`Description
`
`029819.0100—US03
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`FDA Approved Labeling Text dated July 9, 2015 for VIMPAT®
`(lacosamide), available at
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/0222533
`J 030,022254s022,022255s016lb1.pdf (last visited Feb. 2, 2016).
`
`Wolfgang Loscher & Dieter Schmidt, Strategies in Antiepileptic
`Drug Development.‘ Is Rational Drug Design Superior to Random
`Screening and Structural Variation ?, 17 Epilepsy Research 95-134
`(1994).
`
`Michael A. Rogawski & Roger J. Porter, Antiepileptic Drugs:
`Pharmacological Mechanisms and Clinical Efficacy with
`Consideration ofPromising Developmental Stage Compounds, 42(3)
`Pharmacological Reviews 223-86 (1990).
`
`John M. Pellock, Standard Approach to Antiepileptic Drug
`Treatment in the United States 35 (Suppl. 4) Epilepsia S11—S18
`(1994).
`
`Approval Listing dated December 27, 1994 for lamotrigine,
`Approved Drug Products with Therapeutic Equivalence Evaluations
`(Electronic Orange Book),
`http://WWW.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Ap
`pl_No=020241&TABLE1=OB_Rx (last visited Feb. 2, 2016).
`
`2018
`
`The Merck Index 77, 290, 404, 407, 408, 508, 640, 670, 733, 915,
`
`998, 999, 1020, 1028, 1207, 1246, 1247, 1251, 1259, 1260, 1330,
`1654 (Susan Budavari et al. eds., 12th ed. 1996).
`
`2019
`
`2020
`
`Approval Listing dated August 5, 1996 for fosphenytoin sodium,
`Approved Drug Products with Therapeutic Equivalence Evaluations
`(Electronic Orange Book),
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfrn?Ap
`pl_No=020450&TABLE1=OB_Rx (last visited Feb. 2, 2016).
`
`FDA Approved Labeling Text dated January 2014 for CEREBYX®
`(fosphenytoin sodium injection) , available at
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/0204503
`0231bl.pdf (last visited Feb. 2, 2016).
`
`
`
`IPR2016—00204
`
`029819.0100—US03
`
`Exhibit
`
`
`
`Description
`
`Fl
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`ChemIDPlus, Toxnet, U.S. Nat’l Library of Medicine, Beclamide,
`http://chern.sis.nlm.nih.gov/chemidplus/In/501-68-8 (last Visited Feb.
`2, 2016).
`
`ChemIDPlus, Toxnet, U.S. Nat’l Library of Medicine, Phenacemide,
`http://chem.sis.nlm.nih.gov/chemidplus/rn/63—98—9 (last visited Feb.
`2, 2016).
`
`ChemIDPlus, Toxnet, U.S. Nat’1 Library of Medicine, Valproic acid,
`http://chem.sis.nlm.nih.goV/chemidplus/rn/99-66-1 (last Visited Feb.
`2, 2016).
`
`Portfolio — Mont Alto Capital,
`http://wwwmontaltocapital.com/portfolio/ (last Visited Feb. 23,
`2016).
`
`Trial Transcript, UCB, Inc., et al., v. Accord Healthcare, Inc., et. al.,
`No. 13—1206—LPS (D. Del., Nov. 9-13, 2015). (served, but not filed,
`March 17, 2016)
`
`PTAB Telephonic Conference Transcript, IPR2016—00204 (March 8,
`2016).
`
`PTAB Telephonic Conference Transcript, IPR2016—00204 (April 4,
`2016).
`
`2028
`
`PTAB Email to Counsel of Record (January 12, 2016)
`
`Dated: April 18, 2016
`
`Respectfully submitted,
`
`COVINGTON & BURLING LLP
`
`Andrea G. R ister
`
`
`
`One CityCenter
`850 Tenth Street NW
`
`Washington, DC 20001
`(202) 662-6000
`
`Registration No.: 36,253
`Jennifer L. Robbins
`
`Registration No.: 61,163
`Enrique D. Longton
`Registration No.: 47,304
`Attorneys for Patent Owner
`
`
`
`IPR2016-00204
`
`029819.0100-US03
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 18th day of April
`
`2016, the foregoing Patent ()wner’s Exhibit List and Exhibits 2027-2028 were
`
`served by electronic mail, by agreement of the parties, on the following counsel of
`
`record for Petitioner:
`
`Matthew J. Dowd (MatthewDowd@ar1dreWskurth.com)
`Justin W. Crotty (JustinCrotty@andrewskurth.com)
`Andrews Kurth LLP
`
`1350 I Street, NW, Suite 1100
`
`Washington DC 20005
`
`Dated: April 18, 2016
`
`
`drea G. R/ej ter
`Registration No. 36,252: